{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:08:16Z","timestamp":1792789696019,"version":"4.5.0"},"reference-count":52,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T00:00:00Z","timestamp":1771286400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Gilead Sciences (GSRs) SRL Romania"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Breast cancer (BC) is the most common malignant disease in women in Romania, with incidence and mortality rates among the highest in Europe. This consensus statement aims to ensure equitable access to care for human epidermal growth factor receptor 2-negative metastatic BC (HR+\/HER2\u2013 mBC) and triple-negative mBC (mTNBC) in Romania. Between December 2024 and June 2025, a scientific board of 11 oncologists, in collaboration with the Romanian National Society for Medical Oncology (SNOMR), developed national recommendations based on ESMO\/NCCN\/ABC guidelines, clinical expertise, and local conditions. A modified Delphi survey was conducted among medical oncologists to evaluate acceptance of recommendations with greatest clinical impact. Key recommendations included: mandatory biopsy at metastasis with ER\/PgR\/HER2 retesting, HER2-low assessment, and molecular profiling (BRCA, PIK3CA, AKT1\/PTEN, ESR1, plus PD-L1 testing in mTNBC); for HR+\/HER2\u2013 mBC, first-line endocrine therapy plus CDK4\/6 inhibitor, followed by targeted agents, chemotherapy, or antibody\u2013drug conjugates based on progression and visceral crisis; for mTNBC, first-line immune checkpoint inhibitor plus chemotherapy in PD-L1-positive, PARP inhibitors in BRCA-positive patients, and sacituzumab-govitecan or trastuzumab-deruxtecan later; systematic toxicity monitoring; and integrated supportive and palliative care. Sixty-one oncologists completed the survey, with &gt;90% overall agreement, suggesting broad acceptance of recommendations as Romania\u2019s national standard for mBC care.<\/jats:p>","DOI":"10.3390\/curroncol33020120","type":"journal-article","created":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T07:50:30Z","timestamp":1771401030000},"page":"120","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Romanian Consensus Statement for Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer (HR+\/HER2\u2013 mBC) and Triple-Negative Metastatic Breast Cancer (mTNBC)"],"prefix":"10.3390","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5842-1850","authenticated-orcid":false,"given":"Mircea Drago\u0219","family":"Median","sequence":"first","affiliation":[{"name":"Filantropia Clinical Hospital, 011132 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7497-5578","authenticated-orcid":false,"given":"Nicoleta Zenovia","family":"Antone","sequence":"additional","affiliation":[{"name":"Breast Tumors Center, Institute of Oncology \u201cProf. Dr. Ion Chiricuta\u201d, 400015 Cluj-Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Volov\u0103\u021b","sequence":"additional","affiliation":[{"name":"Regional Institute of Oncology, 700483 Ia\u0219i, Romania"},{"name":"Department of Oncology and Radiotherapy, University of Medicine and Pharmacy \u201cGrigore T. Popa\u201d, 700115 Ia\u0219i, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6195-4500","authenticated-orcid":false,"given":"Laura","family":"Mazilu","sequence":"additional","affiliation":[{"name":"Ovidius Clinical Hospital, 905900 Constan\u021ba, Romania"},{"name":"Ovidius University, 900527 Constan\u021ba, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u0218erban Mircea","family":"Negru","sequence":"additional","affiliation":[{"name":"Department of Oncology, Faculty of Medicine, \u2018Victor Babes\u2019 University of Medicine and Pharmacy, 300041 Timi\u0219oara, Romania"},{"name":"Department of Oncology, ONCOHELP Hospital, 300239 Timisoara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R\u0103zvan Ovidiu","family":"Curc\u0103","sequence":"additional","affiliation":[{"name":"Elysee Hospital, 510040 Alba Iulia, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amedeia","family":"Ni\u021b\u0103","sequence":"additional","affiliation":[{"name":"Municipal Hospital, 100337 Ploie\u0219ti, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raluca Ileana","family":"P\u0103tru","sequence":"additional","affiliation":[{"name":"Col\u021bea Clinical Hospital, 030167 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrei","family":"Ungureanu","sequence":"additional","affiliation":[{"name":"Amethyst Radiotherapy Center, 407280 Cluj-Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6840-9310","authenticated-orcid":false,"given":"Vlad","family":"Lupu","sequence":"additional","affiliation":[{"name":"Department of Oncology, Faculty of Medicine, \u2018Victor Babes\u2019 University of Medicine and Pharmacy, 300041 Timi\u0219oara, Romania"},{"name":"Department of Oncology, ONCOHELP Hospital, 300239 Timisoara, Romania"},{"name":"ANAPATMOL Research Center, \u2018Victor Babes\u2019 University of Medicine and Pharmacy, 300041 Timisoara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5000-5422","authenticated-orcid":false,"given":"Cristina Marinela","family":"Oprean","sequence":"additional","affiliation":[{"name":"Department of Oncology, ONCOHELP Hospital, 300239 Timisoara, Romania"},{"name":"ANAPATMOL Research Center, \u2018Victor Babes\u2019 University of Medicine and Pharmacy, 300041 Timisoara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,2,17]]},"reference":[{"key":"ref_1","unstructured":"(2025, October 15). GLOBOCAN 2022. Cancer Today. Available online: https:\/\/gco.iarc.who.int\/today\/en."},{"key":"ref_2","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"ref_3","unstructured":"EUROSTAT (2025, March 22). European Healthy Interview Survey (EHIS). Available online: https:\/\/ec.europa.eu\/eurostat\/web\/microdata\/european-health-interview-survey."},{"key":"ref_4","unstructured":"IOCN, and SCMUT (2025, March 22). Metodologie Cadru Privind Organizarea Programului Na\u021bional de Screening pentru Cancerul de S\u00e2n. Available online: https:\/\/www.spitalul-municipal-timisoara.ro\/public\/data_files\/media\/202104081041-Metodologie%20Call-center.pdf."},{"key":"ref_5","unstructured":"European Commission (2023). Romania: Country Health Profile 2023, OECD."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/j.annonc.2021.09.019","article-title":"ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer","volume":"32","author":"Gennari","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_7","unstructured":"(2025, September 08). NCCN v4.2025 (17.05.2025). Available online: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/breast_blocks.pdf."},{"key":"ref_8","unstructured":"Hofmarcher, T., Berchet, C., and Dedet, G. (2024). Access to oncology medicines in EU and OECD countries. Documents de Travail de l\u2019OCDE sur la Sant\u00e9, OECD."},{"key":"ref_9","unstructured":"Ministry of Health-Rom\u00e2nia (2025, March 22). National Cancer Control and Prevention Plan. Available online: https:\/\/ms.ro\/media\/documents\/Planul_Na%C8%9Bional_de_Combatere_%C8%99i_Control_al_Cancerului_RIQiTXG.pdf."},{"key":"ref_10","unstructured":"Curigliano, G., Castelo-Branco, L., Gennari, A., Harbeck, N., Criscitiello, C., and Trapani, D. (2024, December 28). ESMO Metastatic Breast Cancer Living Guidelines, v1.1 May 2023. Available online: https:\/\/cdn.esmo.org\/guidelines\/living-guidelines\/esmo-living-guideline-metastatic-breast-cancer."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"103756","DOI":"10.1016\/j.breast.2024.103756","article-title":"6th and 7th International consensus guidelines for the management of advanced breast cancer (ABC guidelines 6 and 7)","volume":"76","author":"Cardoso","year":"2024","journal-title":"Breast"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1056\/NEJM197306142882405","article-title":"Medical Assessment by a Delphi Group Opinion Technic","volume":"288","author":"Milholland","year":"1973","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"102511","DOI":"10.1016\/j.ctrv.2023.102511","article-title":"Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer: An Italian consensus paper and critical review","volume":"114","author":"Miglietta","year":"2023","journal-title":"Cancer Treat. Rev."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"3867","DOI":"10.1200\/JCO.22.02864","article-title":"Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: ASCO\u2013College of American Pathologists Guideline Update","volume":"41","author":"Wolff","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_15","unstructured":"(2025, September 03). Breast.Bmk_1.6.0.0. REL_CAPCP. Available online: https:\/\/documents.cap.org\/documents\/New-Cancer-Protocols-March-2025\/Breast.Bmk_1.6.0.0.REL.CAPCP.pdf?_gl=1*141vqn9*_ga*MTMyNzc0ODk0Ni4xNzQ5MzEwNTM2*_ga_97ZFJSQQ0X*czE3NTAyNTUzNTQkbzQkZzEkdDE3NTAyNTU1NTQkajQ5JGwwJGgw."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1056\/NEJMoa1607303","article-title":"Palbociclib and Letrozole in Advanced Breast Cancer","volume":"375","author":"Finn","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/j.annonc.2024.04.013","article-title":"Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: Final overall survival results of MONARCH 3","volume":"35","author":"Goetz","year":"2024","journal-title":"Ann. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/S1470-2045(18)30292-4","article-title":"Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): A randomised phase 3 trial","volume":"19","author":"Tripathy","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1056\/NEJMoa1903765","article-title":"Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer","volume":"381","author":"Im","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1093\/annonc\/mdy155","article-title":"Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer","volume":"29","author":"Hortobagyi","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"104103","DOI":"10.1016\/j.esmoop.2024.104103","article-title":"Comparative overall survival of CDK4\/6 inhibitors plus an aromatase inhibitor in HR+\/HER2- metastatic breast cancer in the US real-world setting","volume":"10","author":"Rugo","year":"2025","journal-title":"ESMO Open"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S1470-2045(15)00613-0","article-title":"Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): Final analysis of the multicentre, double-blind, phase 3 randomised controlled trial","volume":"17","author":"Cristofanilli","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1001\/jamaoncol.2019.4782","article-title":"The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial","volume":"6","author":"Sledge","year":"2020","journal-title":"JAMA Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1200\/JCO.2018.78.9909","article-title":"Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3","volume":"36","author":"Slamon","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa1911149","article-title":"Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer","volume":"382","author":"Slamon","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"3246","DOI":"10.1200\/JCO.22.00338","article-title":"Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor\u2013Positive, Human Epidermal Growth Factor Receptor 2\u2013Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial","volume":"40","author":"Bidard","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1056\/NEJMoa1813904","article-title":"Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer","volume":"380","author":"Ciruelos","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.annonc.2020.11.011","article-title":"Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2\u2013negative advanced breast cancer: Final overall survival results from SOLAR-1","volume":"32","author":"Ciruelos","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1056\/NEJMoa2214131","article-title":"Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer","volume":"388","author":"Turner","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1056\/NEJMoa2407086","article-title":"Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer","volume":"391","author":"Bardia","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"3365","DOI":"10.1200\/JCO.22.01002","article-title":"Sacituzumab Govitecan in Hormone Receptor\u2013Positive\/Human Epidermal Growth Factor Receptor 2\u2013Negative Metastatic Breast Cancer","volume":"40","author":"Rugo","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1056\/NEJMoa2202809","article-title":"Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer","volume":"387","author":"Cortes","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1056\/NEJMoa1809615","article-title":"Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer","volume":"379","author":"Schmid","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1056\/NEJMoa1706450","article-title":"Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation","volume":"377","author":"Robson","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.ejca.2023.01.031","article-title":"OlympiAD extended follow-up for overall survival and safety: Olaparib versus chemotherapy treatment of physician\u2019s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer","volume":"184","author":"Robson","year":"2023","journal-title":"Eur. J. Cancer"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1200\/JCO.2014.59.5298","article-title":"Randomized Phase III Trial of Paclitaxel Once Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First-Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB 40502\/NCCTG N063H (Alliance)","volume":"33","author":"Rugo","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","article-title":"Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer","volume":"384","author":"Bardia","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"GS3-06","DOI":"10.1158\/1538-7445.SABCS20-GS3-06","article-title":"Abstract GS3-06: Biomarker evaluation in the phase 3 ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer","volume":"81","author":"Hurvitz","year":"2021","journal-title":"Cancer Res."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1056\/NEJMoa1814213","article-title":"Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer","volume":"380","author":"Bardia","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.annonc.2023.05.008","article-title":"ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer","volume":"34","author":"Tarantino","year":"2023","journal-title":"Ann. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1002\/cncr.34904","article-title":"A review of treatment options in HER2-low breast cancer and proposed treatment sequencing algorithm","volume":"129","author":"Roy","year":"2023","journal-title":"Cancer"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s40291-025-00777-7","article-title":"Clinical Actionability of Molecular Targets in Multi-Ethnic Breast Cancer Patients: A Retrospective Single-Institutional Study","volume":"29","author":"Kang","year":"2025","journal-title":"Mol. Diagn. Ther."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Popovi\u0107, L., Bor\u0161tnar, S., Bo\u017eovi\u0107-Spasojevi\u0107, I., Cvetanovi\u0107, A., Dedi\u0107 Plaveti\u0107, N., Kaneva, R., Konsoulova, A., Matos, E., Tomi\u0107, S., and Vrdoljak, E. (2025). Treatment Sequencing in Metastatic HR+\/HER2- Breast Cancer: A Delphi Consensus. Cancers, 17.","DOI":"10.3390\/cancers17091412"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"101381","DOI":"10.1016\/j.esmoop.2023.101381","article-title":"192MO DESTINY-Breast04 subgroup analyses of trastuzumab deruxtecan (T-DXd) vs treatment of physician\u2019s choice (TPC) in patients (pts) with human epidermal growth factor 2 (HER2)-low, estrogen-receptor (ER) expression immunohistochemistry (IHC) 0\u201310% metastatic breast cancer (mBC)","volume":"8","author":"Cameron","year":"2023","journal-title":"ESMO Open"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1158\/2159-8290.CD-21-0702","article-title":"Parallel Genomic Alterations of Antigen and Payload Targets Mediate Polyclonal Acquired Clinical Resistance to Sacituzumab Govitecan in Triple-Negative Breast Cancer","volume":"11","author":"Coates","year":"2021","journal-title":"Cancer Discov."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1200\/JCO.2023.41.16_suppl.1022","article-title":"Sequential use of antibody-drug conjugate after antibody-drug conjugate for patients with metastatic breast cancer: ADC after ADC (A3) study","volume":"41","author":"Abelman","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1038\/s41416-024-02766-9","article-title":"Efficacy of administration sequence: Sacituzumab Govitecan and Trastuzumab Deruxtecan in HER2-low metastatic breast cancer","volume":"131","author":"Poumeaud","year":"2024","journal-title":"Br. J. Cancer"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"e2400898","DOI":"10.1200\/PO-24-00898","article-title":"Sequential Antibody-Drug Conjugate Therapy in Patients with Metastatic Breast Cancer Treated with Sacituzumab Govitecan and Trastuzumab Deruxtecan","volume":"9","author":"Mai","year":"2025","journal-title":"JCO Precis. Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1186\/s13690-024-01353-x","article-title":"Applying a \u201cmedical deserts\u201d lens to cancer care services in the North-West region of Romania from 2009 to 2022\u2013a mixed-methods analysis","volume":"82","author":"Ungureanu","year":"2024","journal-title":"Arch. Public Health"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"S67","DOI":"10.1016\/j.jpainsymman.2017.03.036","article-title":"Palliative Care in Romania","volume":"55","author":"Mosoiu","year":"2018","journal-title":"J. Pain Symptom Manag."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"E109","DOI":"10.1097\/NJH.0000000000000969","article-title":"Translating Knowledge Into Clinical Practice: A Unique End-of-Life Nursing Education Consortium Teleconferencing Program","volume":"25","author":"Mitrea","year":"2023","journal-title":"J. Hosp. Palliat. Nurs."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/33\/2\/120\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T12:08:20Z","timestamp":1771416500000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/33\/2\/120"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,17]]},"references-count":52,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["curroncol33020120"],"URL":"https:\/\/doi.org\/10.3390\/curroncol33020120","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,17]]}}}